🧾 What This Document Is

This is an 8-K filing, which is like a major news alert a public company sends to the SEC and investors. This specific one includes a press release (the exhibit) where Connect Biopharma reports its 2025 financial results and gives a big update on its business progress.

👉 Why it matters: It's a snapshot of where the company stands financially and a progress report on its main drug, helping investors understand its current health and future potential.

🏢 What The Company Does

Connect Biopharma is a clinical-stage biopharmaceutical company. In simple terms, they are a biotech startup that doesn't sell any products yet. They spend their time and money researching and developing new drugs.

👉 Focus: They are focused on transforming care for inflammatory diseases, specifically asthma and COPD (Chronic Obstructive Pulmonary Disease). Their main drug candidate is called rademikibart.

🚀 Clinical & Business Highlights

This section covers the key announcements from the past few months.

💊 Rademikibart's Clinical Progress

The company shared several important updates on their lead drug, rademikibart:

• Positive Phase 1 IV Data (March 2026): A study giving rademikibart as a short IV push to asthma/COPD patients showed it worked fast. Many patients saw a ≥200 mL improvement in their lung function (FEV1) within just 15 minutes, and the benefit lasted for about a month. This is exciting because it suggests the drug has a quick, bronchodilator effect.
• Phase 3 Results in Eczema Presented (March 2026): Results from a Phase 3 study in moderate-to-severe atopic dermatitis (AD) showed the drug was effective and safe. These results were important enough to be presented in a special "Late-Breaking Research" session at a major dermatology conference (AAD).
• New Science Supports Differentiation (January 2026): New lab data provides a scientific reason why rademikibart might work differently and potentially better than a similar existing drug (dupilumab), especially for lung function.
• Ongoing Mid-Size Trials: They are actively recruiting patients for two Phase 2 "Seabreeze STAT" studies. These are testing rademikibart as an add-on treatment for acute flare-ups (exacerbations) of asthma and COPD. Top-line data from these is expected mid-2026.

💼 Corporate Move

• New Funding Secured (March 2026): They signed a deal to raise $20.2 million by selling new shares directly to institutional investors. This is crucial for funding their operations.

💰 Financial Snapshot (for 2025)

Here's a simplified look at their finances for the year ended December 31, 2025. Remember, as a clinical-stage company, they are spending more than they earn.

• Cash on Hand: They started 2026 with $44.3 million in cash and investments. With the new $20.2 million raise, they expect this money to last into the second half of 2027.
• Revenue: They had $64,000 in revenue for 2025, all from cost reimbursements under a partnership deal. This is down significantly from $26 million in 2024, which included large upfront payments.
• R&D Spending: Their research costs were $37.8 million for 2025, up from $29.3 million in 2024. This increase is mainly because they started those new Phase 2 asthma/COPD trials.
• Overall Loss: Their net loss for 2025 was $55.5 million, or $1.00 per share. This is larger than their 2024 loss of $15.6 million, reflecting their increased clinical trial spending.

💸 The New $20.2 Million Lifeline

This equity raise is a critical move for the company.

• The Deal: They sold 6.13 million new shares at $3.25 per share to a select group of institutional investors.
• Net Proceeds: After fees and expenses (about $1.6 million), they expect to pocket around $18.6 million.
• The Big Why: This money extends their cash runway from likely 2026 to the second half of 2027. This gives them a much longer window to generate data from their ongoing Phase 2 trials and potentially attract partners or investors.

🔮 What's Next

The company's immediate future hinges on a few key events:

• Mid-2026 Data: The most anticipated milestones are the top-line results from the Phase 2 Seabreeze STAT studies for acute asthma and COPD exacerbations. Success here would be a major proof point for the drug in these new areas.
• Partnership Potential: Their partnership with Simcere in Greater China is already in place. They are eligible for up to $110 million more in milestone payments if Simcere achieves certain development, regulatory, and commercial goals there.
• Trial Progress: They will continue enrolling patients in their ongoing studies and preparing for the next phases of development.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths

• Promising Drug Profile: Early data suggests rademikibart may have a unique, fast-acting mechanism in the lungs, potentially setting it apart from competitors.
• Validated Partnership: The Simcere deal provides validation and a potential path to significant future payments (~$110M in milestones + royalties).
• Funded Through 2027: The recent financing removes immediate cash pressure, allowing the company to focus on executing its clinical plans.

⚠️ Risks

• Clinical & Regulatory Risk: The biggest risk is that future trials fail to show the drug works well enough to get approved by regulators like the FDA.
• Heavy Cash Burn: The company is losing money every year ($55.5M in 2025) and is entirely reliant on its cash reserves and ability to raise more money in the future.
• Competition: The asthma and COPD drug market is crowded with established and effective treatments.

🧠 The Analogy

Connect Biopharma is like a high-performance engine builder in a garage. They've built a promising new engine (rademikibart) and have shown it can start incredibly fast (Phase 1 data) and runs efficiently in one car type (eczema trials). Now, they're installing it into two new race cars (the Phase 2 asthma and COPD studies) to see if it can win in different conditions. They just secured a big sponsorship (the $20.2M raise) to pay for the fuel and parts needed to run these crucial races, which happen mid-next year.

📇 Key Contacts & People

• Barry Quart, Pharm.D. - Chief Executive Officer and Director
• Investor Relations: Alex Lobo, Precision AQ, [email protected], (212) 698-8802
• Media Contacts:
  • Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC, [email protected]
  • David Schull, Russo Partners, LLC, [email protected], (858) 717-2310 or (646) 942-5604

🧩 Final Takeaway

Connect Biopharma is a well-funded clinical-stage biotech with a promising lung drug (rademikibart) that showed exciting fast-acting data. Its entire near-term future depends on the make-or-break results from two key trials (for acute asthma and COPD flare-ups) expected in the second half of 2026.